

**EUROPEAN
CURRICULUM VITAE**



PERSONAL INFORMATION

Name	ALESSANDRO BUDA
Address	
Phone number	+39. 349 5239877
Fax	
E-mail	alebuda1972@gmail.com
country	ITALY
Born date	28/07/1972

JOB EXPERIENCES

- Date (from – to) 12/05 to date
MD Gynecologist at the Division of Gynecology and Obstetrics at San Gerardo Hospital, Monza, Milan (Italy)
From 2015
Chief Gynecology Oncology Surgical Unit, San Gerardo Hospital, University of Milano Bicocca, Monza
- hospital SAN GERARDO HOSPITAL, UNIVERSITY OF MILANO-BICOCCA, MONZA, MILAN
- degree MD
- main field of activity HIGH SPECIALIZATION IN GYNECOLOGIC ONCOLOGY SURGERY FROM 2011; SPECIALIST IN ONCOLOGICAL SURGERY AND PELVIC SURGERY, MININVASIVE LAPAROSCOPIC SURGERY (ONCOLOGICAL AND BENIGN OBSTETRICS & GYNECOLOGICAL DISEASE) WITH MORE THAN **5000** ADVANCED PROCEDURES PERFORMED FROM 2004 TO DATE (OPEN SURGERY, LAPAROSCOPIC AND VAGINALLY) MOST OF THEM INCLUDING ADVANCED GYN ONCOLOGY RADICAL PROCEDURE FOR OVARIAN, CERVICAL, VULVAR and ENDOMETRIAL CANCER.
WORLDWIDE ITALIAN REFERENCE FOR SENTINEL NODE MAPPING WITH FLUORESCENT DYE USING ICG (SEE PAPERS INCLUDED)

CERTIFICATIONS

- Date (from – to) 1999

Medical Doctor at the University of Milan with the tesi entitled: prognostic significance of the expression of phosphatase CDC25A, B and C in advanced ovarian cancer.

Spring-summer 1997

Researcher at The Laboratory of Biomolecular Epidemiology
(Center for Nutrition and Toxicology, Department of Bioscience NOVUM),
Karolinska University-Stockholm – ERASMUS project award

From 1998 to date

Collaboration on gynecological oncologic project and research with the Laboratory of Clinical Oncological Research at the "Mario Negri" Institute of Milan

12/2005

Gynecologist degree at the University of Milano-Bicocca with the thesis entitled: the Role of pathological response as early indicator of efficacy in neoadjuvant chemotherapy to radical surgery in locally advanced cervical cancer.

05/2012

Residence at Gynecologic Department Memorial Sloan Kettering Cancer Center, New York under the supervision of Professor N Abu Rustum

04/2017

Observe ship MD Anderson Cancer Center Houston, Texas

11/ 2016

Applied the national documents for Assistant Professor

FIRST LANGUAGE

ITALIAN

OTHERS

ENGLISH, SPANISH

SOFTWARE ABILITY

WELL KNOWN PROGRAMS OF WINDOWS OFFICE E MAC;
Internet Explorer, WORD, POWER POINT, ACCESS, EXCEL, SAS system version 6.12

DRIVE LICENCE

TYPE B

OTHER INFORMATION

ESGO Member 2010-2011-2012-2013-2015; ESGE member 2010-2011; SIOG member 2012-13-15, IGCS Member 2016


FILE ENCLOSED

MAJOR INTERNATIONAL PUBLICATIONS

Monza, March 2019

Signature

ALESSANDRO BUDA



International major publications

1) E Mari, I Floriani, A Tinazzi, **A Buda**, et al.

Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials.

Ann Oncol 11: 837-843, 2000

2) The ICON Collaborators (**A Buda**, name listed in ICON group)

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

The Lancet, 360: 505-515, 2002

3) MG Cantù, **A Buda**, G Parma, et al.

Randomised controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.

J Clin Oncol, 20 (5): 1232-1237, 2002

4) G Zanetta, S Rota, A Lissoni, A Meni, G Brancatelli and **A Buda**

Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors

Gynecol Oncol, 81: 63-66-2001

5) ICON1 and EORTC-ACTION collaborators (**Alessandro Buda**, name listed in ICON office Mario Negri Institute, Italy).

International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

J Natl Cancer Inst 2003; 95: 105-112

6) ICON1 collaborators (**A Buda**, name listed in ICON office Mario Negri Institute, Italy)

International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer

J Natl Cancer Inst 2003; 95: 125-132

7) **Buda A**, Dell'Anna T, Signorelli M and Mangioni C

Role of ifosfamide in cervical cancer. an overview

Oncol, 65 (suppl. 2): 63-66, 2003

8) Manenti L, Paganoni P, Floriani I, Torri V, **Buda A**, Landoni F, Taraboletti G, Belotti D, Giavazzi R.

Expression level of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in plasma of patients with ovarian carcinoma.

Eur J Cancer, 39: 1948-1956, 2003

9) Torri V, Floriani I, Poli D, Santillo M, **Buda A**

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Lancet , 361: 2099-2106 (362: 1504, 2003)

10) **Buda A**, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C.

Randomised controlled trial comparing single agent paclitaxel versus epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the “Mario Negri” Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group.

Br J Cancer, 90: 2112-2117, 2004

11) G Apolone, **A Buda**.

Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality of life evaluation?

Ann Oncol, 15(9):1443-4, 2004

12) G Cavaletti, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, D Franchi, MT La Presa, A Lissoni, **A Buda**, F Fei, S Cundari, C Zanna.

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

Ann Oncol. 15(9):1439-42, 2004.

13) Bonazzi C, Urso M, Dell'Anna T, Sacco S, **Buda A**, Cantu MG.

Placental site trophoblastic tumor: an overview.

J Reprod Med, 49(8):585-588, 2004

14) **A Buda**, R Fossati, N Colombo et al.

Randomized Trial of Neoadjuvant Chemotherapy Comparing a Three-Drug Combination of Paclitaxel, Ifosfamide, and Cisplatin Versus Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 Italian Collaborative Study

J Clin Oncol, 23: 4137-4145 , 2005

15) S Sironi , **A Buda**, M Picchio, et al.

Lymph node metastasis in patients with clinical early stage cervical cancer: detection with integrated FDG PET/CT

Radiology 238 (1): 272-279, 2006

16) **A Buda**, L Ferrari, C Marra et al.

Vulvar endometriosis in surgical scar after excision of the Bartholin gland: report of a case.

Arch Gynecol Obstet 277 (3): 255-6, 2007

17) **A Buda**, G Pizzocaro, P Ceruti et al.

Case report: renal cell carcinoma presenting as hypertension in pregnancy.

Arch Gynecol Obstet 277 (3): 263-5, 2007

18) Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, **Buda A**, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E.

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.

Ann Oncol. 2009 20(4):660-519)

19) Pellegrino A, Signorelli M, Fruscio R, Villa A, **Buda A**, Beretta P, Garbi A, Vitobello D.

Feasibility and morbidity of total laparoscopic radical hysterectomy with or without pelvic lymphadenectomy in obese women with stage I endometrial cancer.

Arch Gynecol Obstet 2009; 279(5): 655-60

20) **Buda A**, Pellegrino A, Vitobello D, Meroni MG, Recalcati D, Perego P.

Total laparoscopic radical parametrectomy, partial colpectomy, and pelvic lymphadenectomy in patients with occult cervical cancer.

Int J Gynaecol Obstet. 2009 Oct;107(1):73-6.

22) Signorelli M, Guerra L, **Buda A**, Picchio M, Mangili G, Dell'Anna T, Sironi S, Messa C.

Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.

Gynecol Oncol. 2009 Nov;115(2):231-5.

23) Signorelli M, Fruscio R, Dell'Anna T, **Buda A**, Giuliani D, Ceppi L, Milani R.

Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review.

Int J Gynecol Cancer. 2010 Nov;20(8):1363-6.22

24) Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, **Buda A**, Romualdi C, D'Incalci M.

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Lancet Oncol. 2011 Mar;12(3):273-85.

25) Signorelli M, Guerra L, Montanelli L, Crivellaro C, **Buda A**, Dell'Anna T, Picchio M, Milani R, Fruscio R, Messa C
Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?

Gynecol Oncol. 2011 Nov;123(2):236-40.

26) Misani M, Rovati LC, Confalonieri P, **Buda A**, Giuliani D, Del Bene M.

Modified lotus petal flap for vulvo-vaginal reconstruction after resection for vulvar cancer: a single institution experience.

Handchir Mikrochir Plast Chir. 2011 Aug;43(4):250-4.

27) **Buda A**, Giuliani D, Montano N, Perego P, Milani R.

Primary insular carcinoid of the ovary with carcinoid heart disease: unfavorable outcome of a case.

International Journal of Surgery Case Reports 2012; 3(2): 59-61.

28) **Alessandro Buda**, Pier Luigi Confalonieri, Luca Carlo Vittorio Rovati, Robert Fruscio, Daniela Giuliani, Mauro Signorelli, Tiziana Dell'Anna, Cecilia Pirovano, Rodolfo Milani

Better anatomical and cosmetic results using tunnelled lotus petal flap for plastic reconstruction after demolitive surgery for vulvar malignancy.

Int J Gynecol Cancer 2012; 22 (5): 860-4

29) **A Buda**, R Fruscio, C Pirovano, M Signorelli, M Betti, R Milani.

TachoSil patch for the prevention of postoperative complications after groin dissection in gynecological malignancy.

Int J Obstet Gynecol 2012; 117 (3): 217-9

30) **Alessandro Buda**, Federica Elisei, Maurizio Arosio, Carlotta Dolci, Mauro Signorelli, Patrizia Perego, Daniela Giuliani, Dario Recalcati, Giorgio Cattoretti, Rodolfo Milani, Cristina Messa

Integration of hybrid SPECT/CT in the preoperative assessment of sentinel node in patients with uterine cancer: our experience and literature review.

Int J Gynecol Cancer 2012; 22 (5): 830-5

31) **Buda A**, Confalonieri PL, Rovati LC, Signorelli M, Del Bene M.

Tunneled modified lotus petal flap for surgical reconstruction of severe introital stenosis after radical vulvectomy.

Int J Surg Case Rep. 2012;3(7):299-301.

32) Caiola E, Rulli E, Fruscio R, **Buda A**, Brogginì M, Marabese M.

KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.

Am J Cancer Res. 2012;2(3):298-308.

33) Crivellaro C, Signorelli M, Guerra L, De Ponti E, **Buda A**, Dolci C, Pirovano C, Todde S, Fruscio R, Messa C.

18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.

Gynecol Oncol. 2012; 127 (1): 131-5.

34) Dell' Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, Milani R, Bocciolone L, **Buda A**, Mangioni C, Scambia G, Angioli R, Campagnutta E, Grassi R, Landoni F.

Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Br J Cancer. 2012 Aug 21;107(5):785-92.

- 35) Crivellaro C, Signorelli M, Guerra L, De Ponti E, Pirovano C, Fruscio R, Elisei F, Montanelli L, **Buda A**, Messa C. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol. 2013 Aug;130(2):306-11. doi: 10.1016/j.ygyno.2013.05.011. Epub 2013 May 23.
- 36) **Buda A**, Elisei F, Dolci C, Cuzzocrea M, Milani R. Uterine lymphatic drainage is unaffected from injection technique and operators: Identical sentinel node detection in two cases of endometrial cancer. Int J Surg Case Rep. 2013;4(8):697-9. doi: 10.1016/j.ijscr.2013.04.038. Epub 2013 May 22.
- 37) Fagotti A, Vizzielli G, De Iaco P, Surico D, **Buda A**, Mandato VD, Petruzzelli F, Ghezzi F, Garzarelli S, Mereu L, Viganò R, Tateo S, Fanfani F, Scambia G. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013 Jul 24. doi:pii: S0002-9378(13)00748-5. 10.1016/j.ajog.2013.07.016.
- 38) **Buda A**, Marco C, Dolci C, Elisei F, Baldo R, Locatelli L, Milani R, Messa C. Sentinel node mapping in high-risk endometrial cancer after laparoscopic supracervical hysterectomy with morcellation. Int J Surg Case Rep. 2013;4(10):809-12. doi: 10.1016/j.ijscr.2013.06.010.
- 39) Signorelli M, Guerra L, Pirovano C, Crivellaro C, Fruscio R, **Buda A**, Cuzzocrea M, Elisei F, Ceppi L, Messa C. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: A prospective study. Gynecol Oncol. 2013 Aug 27. DOI: pii: S0090-8258(13)01107-4. 10.1016/j.ygyno.2013.08.022.
- 40) Evaluation of Patient Satisfaction Using the EORTC IN-PATSAT32 Questionnaire and Surgical Outcome in Single-Port Surgery for Benign Adnexal Disease: Observational Comparison with Traditional Laparoscopy. **Buda A**, Cuzzocrea M, Montanelli L, Passoni P, Bargossi L, Baldo R, Locatelli L, Milani R. Diagn Ther Endosc. 2013;2013:578392.
- 41) Somaini M, Brambillasca P, Ingelmo PM, Lovisari F, Catenacci SS, Rossini V, Bucciero M, Sahillioglu E, **Buda A**, Signorelli M, Gili M, Joshi G, Fumagalli R, Ferland CE, Diemunsch P. Effects of peritoneal ropivacaine nebulization for pain control after laparoscopic gynecologic surgery. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):863-9. DOI: 10.1016/j.jmig.2014.03.021.
- 42) **Buda A**, Guerra L, Signorelli M. Regarding: "pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging". Int J Gynecol Cancer. 2014 Jul; 24 (6): 964-5. doi: 10.1097/IGC.0000000000000159.
- 43) **Buda A**, Guerra L, Crivellaro C. Comment on 'Pre-operative nomogram for the identification of lymph node metastasis in early cervical cancer". Br J Cancer. 2014 Aug 14. doi: 10.1038/bjc.2014.284.
- 44) Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, **Buda A**, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014 Oct 10. pii: canres.0274.2014.
- 45) Scalia Catenacci S, Lovisari F, Peng S, Allegri M, Somaini M, Ghislanzoni L, Greco M, Rossini V, D'Andrea L, **Buda A**, Signorelli M, Pellegrino A, Sportiello D, Bugada D, Ingelmo PM. Postoperative Analgesia after Laparoscopic Ovarian Cyst Resection: Double-blind Multicenter Randomized Control Trial Comparing Intraperitoneal Nebulization and Peritoneal Instillation of Ropivacaine. J Minim Invasive Gynecol. 2015 Jul-Aug;22(5):759-66.

- 46) Signorelli M, Crivellaro C, **Buda A**, et al.
Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping.
Clin Nucl Med. 2015 Oct; 40(10):780-5.
- 47) **Buda A**, Lissoni AA, Floriani I, et al
Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival.
Int J Gynecol Cancer. 2015 Oct;25(8):1468-75.
- 48) **Buda A**, Di Martino G, Vecchione F, et al.
Optimizing Strategies for Sentinel Lymph Node Mapping in Early-Stage Cervical and Endometrial Cancer: Comparison of Real-Time Fluorescence With Indocyanine Green and Methylene Blue.
Int J Gynecol Cancer. 2015 Oct;25(8):1513-8.
- 49) **Buda A**, Bussi B, Di Martino G, et al.
Sentinel Lymph Node Mapping With Near-Infrared Fluorescent Imaging Using Indocyanine Green: A New Tool for Laparoscopic Platform in Patients With Endometrial and Cervical Cancer.
J Minim Invasive Gynecol. 2015 Oct 8. DOI: 10.1016/j.jmig.2015.09.022.
- 50) **Buda A**, Lissoni A, Milani R
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral vs cervical injection.
J Gynecol Oncol. 2016 Jan; 27(1): e11
- 51) **A Buda**, C Crivellaro, F Elisei et al.
Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer 99mTc and/or Blue Dye
Ann Surg Oncol, 2016 DOI 10.1245/s10434-015-5022-1
- 52) **A Buda**, A Ghelardi, R Fruscio et al.
The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study.
Eur J Obstet Gynecol & Repr Biol 2016; 197: 165-8. DOI DOI: 10.1016/j.ejogrb.2015.12.005.
- 53) **A Buda**, Pierluigi Confalonieri, LC Rovati
Regarding: "Vulvar Reconstruction by Perforator Flaps. Algorithm for Flap Choice Based on the Topography of the Defect".
Int J Gynecol Cancer 2016; 26 (2): 224-225.
- 54) **Buda A**, Dell'Anna T, Vecchione F, Verri D, Di Martino G, Milani R.
Near-Infrared Sentinel Lymph Node Mapping With Indocyanine Green Using the VITOM II ICG Exoscope for Open Surgery for Gynecologic Malignancies.
J Minim Invasive Gynecol. 2016 Feb 24. pii: S1553-4650(16)00118-7. DOI: 10.1016/j.jmig.2016.02.015.
- 55) **Buda A**, Elisei F, Palazzi S, et al.
Quality of Care for Cervical and Endometrial Cancer Patients: The Impact of Different Techniques of Sentinel Lymph Node Mapping on Patient Satisfaction.
Ann Surg Oncol. 2016 Apr 26.
- 56) **Buda A**, Papadia A, Zapardiel I, et al.
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach.

Ann Surg Oncol. 2016 Apr 28.

57) **Buda A**, Passoni P, Corrado G, et al.

Near-infrared Fluorescence-guided Sentinel Node Mapping of the Ovary With Indocyanine Green in a Minimally Invasive Setting: A Feasible Study.

J Minim Invasive Gynecol. 2016 Sep 23. pii: S1553-4650(16)31046-9. doi: 10.1016/j.jmig.2016.09.006.

58) Papadia A, Zapardiel I, Bussi B, Ghezzi F, Ceccaroni M, De Ponti E, Elisei F, Imboden S, de la Noval BD, Gasparri ML, Di Martino G, De Santiago J, Mueller M, Vecchione F, Dell'Orto F, **Buda A**.

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye.

J Cancer Res Clin Oncol. 2016 Nov 3.

59) Elisei F, Crivellaro C, Giuliani D, Dolci C, De Ponti E, Montanelli L, La Manna M, Guerra L, Arosio M, Landoni C, **Buda A**.

Sentinel-node mapping in endometrial cancer patients: comparing SPECT/CT, gamma-probe and dye.

Ann Nucl Med. 2016 Nov 4.

60) Confalonieri P, Gilardi R, Rovati LC, Ceccherelli A, Lee JH, Magni S, Del Bene M, **Buda A**.

Comparison of V-Y advancement flap versus Lotus Petal Flap for plastic reconstruction after surgery in case of vulvar malignancies: a retrospective single center experience.

Ann Plast Surg 2017; 79 (2): 186-191.

61) Di Martino G, Crivellaro C, De Ponti E, Bussi B, Papadia A, Zapardiel I, Vizza E, Elisei F, Diestro MD, Locatelli L, Gasparri ML, Di Lorenzo P, Mueller M, **Buda A**.

Indocyanine Green versus Radiotracer with or without Blue Dye for Sentinel Lymph Node Mapping in Stage >IB1 Cervical Cancer (>2 cm).

J Minim Invasive Gynecol. 2017 May 29. pii: S1553-4650(17)30305-9.

62) **Buda A**, Passoni P, Reato C, Di Martino G.

Laparoscopic minimally invasive approach to sentinel lymph node mapping of the ovary using the near-infrared fluorescent S1 HD Pinpoint system with indocyanine green dye.

J Minim Invasive Gynecol. 2017; 25(2):336-337

63) **Buda A**, Di Martino G, De Ponti E, Passoni P, Sina F, Reato C, Vecchione F, Giuliani D.

Laparoscopic Sentinel Node Mapping in Cervical and Endometrial Malignancies: a Case Control Study Comparing Two Near-Infrared Fluorescence Systems.

J Minim Invasive Gynecol. 2017 Aug 11. doi: 10.1016/j.jmig.2017.08.011.

64) Papadia A, Gasparri ML, **Buda A**, Mueller MD.

Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue.

J Cancer Res Clin Oncol. 2017 Aug 21. doi: 10.1007/s00432-017-2501-8.

65) **Alessandro Buda**, Giampaolo Di Martino, Stefano Restaino, Elena De Ponti, Giorgia Monterossi, Daniela Giuliani, Alfredo Ercoli, Federica Dell'Orto, Giorgia Dinoi, Tommaso Grassi, Giovanni Scambia, MD, Francesco Fanfani.

The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two reference centers.

Gynecol Oncol 2017; 147(3): 528-534

66) Di Martino G, Reato C, Verri D, Dell'Orto F, **Buda A**.

Laparoscopic Typical and Atypical Locations of Sentinel Node Mapping with Indocyanine Green: Comparison of Two Near-Infrared Fluorescence Systems.

J Minim Invasive Gynecol. 2017, 25(3):384-385

- 67) Uccella S, **Buda A**, Morosi C, Di Martino G, Delle Marchette M, Reato C, Casarin J, Ghezzi F. Minilaparoscopy vs Standard Laparoscopy for Sentinel Node Dissection: A Pilot Study. J Minim Invasive Gynecol. 2018; 25 (3): 461-466.
- 68) A Rare Case Report: Isolated Mediastinal Lymph Node Recurrence in High-Risk Endometrial Cancer at 5 Years after Primary Laparoscopic Surgery. Montanelli L, Reato C, Mauro S, Meregalli S, Spallino M, **Buda A**. J Minim Invasive Gynecol. 2018; 25 (3): 537-540.
- 69) Crivellaro C, Guglielmo P, De Ponti E, Elisei F, Guerra L, Magni S, La Manna M, Di Martino G, Landoni C, **Buda A**. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? Medicine (Baltimore). 2017; 96 (38): e7943.
- 70) **Alessandro Buda**, Maria Luisa Gasparri, Andrea Puppo, Liliana Mereu, Elena De Ponti, ¹Giampaolo Di Martino, Antonia Novelli, ⁴Saverio Tateo, Michael Muller, Fabio Landoni, Andrea Papadia. Lymph node evaluation in high-risk early stage endometrial cancer: a multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy. Gynecol Oncol 2018, 150 (2): 261-266
- 71) De Bernardi E, **Buda A**, Guerra L, Vicini D, Elisei F, Landoni C, Fruscio R, Messa C, Crivellaro C. Radiomics of the tumour as a tool to improve 18F-FDG-PET sensitivity in detecting nodal metastases in endometrial cancer. EJNMMI Res. 2018 Aug 22;8 (1):86. doi: 10.1186/s13550-018-0441-1.
- 72) **Buda A**, Restaino S, Di Martino G, De Ponti E, Monterossi G, Dinoi G, Magni S, Quagliozzi L, Dell'Orto F, Ciccarone F, Lamanna M, Scambia G, Landoni F, Fanfani F. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study. Eur J Surg Oncol. 2018 Jul 24. pii: S0748-7983(18)31187-9. doi: 10.1016/j.ejso.2018.06.034.
- 73) Papadia A, **Buda A**, Gasparri ML, Di Martino G, Bussi B, Verri D, Mueller MD. The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage endometrial cancer. J Cancer Res Clin Oncol. 2018 Jul 24. doi: 10.1007/s00432-018-2716-3.
- 74) De Bernardi E, **Buda A**, Guerra L, et al. Radiomics of the primary tumour as a tool to improve 18-FDG-PET sensitivity in detecting nodal metastases in endometrial cancer EJNMMI Res. 2018 22; 8 (1): 86. doi: 10.1186/s13550-018-0441-1.
- 75) **Buda A**, Restaino S, Di Martino G, et al. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study. Eur J Surg Oncol. 2018; 44 (10): 1562-1567.
- 76) Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, **Buda A**, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebiski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018 5;379 (20): 1895-1904.

Medical book and collaborations

1) F Landoni, F Vecchione, T Dell'Anna, C Mangioni, C Bonazzi, **A Buda**, M Zoccatelli.

I tumori dell'ovaio.

In Trattato di Chirurgia Oncologica, Capitolo 74; Vol III. Ed. Piccin 2002.

2) Clinical Evidence: Translation CE FULL TEXT chapters on women health

In Clinical Evidence, Italian Edition, 3, 2005 (edizione integrale online: <http://aifa.clinev.it>)

3) Clinical Evidence: Translation CE FULL TEXT chapters on women health

In Clinical Evidence, Italian Edition, 4, 2006 (edizione integrale online:

<http://aifa.clinev.it>)

4) Italian Guidelines in Oncology 2015 – Chapter on Cervical cancer sentinel node mapping

4) DVD entitled: totally laparoscopic radical hysterectomy with pelvic lymphadenectomy.

Pellegrino A, Vitobello D, Meroni M, N Iedà, **A Buda**. Istituto di scienze Biomediche, Università degli Studi Milano-Bicocca, San Gerardo dei Tintori Monza, Clinica di Ostetricia e Ginecologia

In collaborazione con AB Medica, Cooper Surgical, Gyrus Acmi, Taut, Vims, 2007